Project description:There is an urgent need for early detection of Pancreatic ductal adenocarcinoma (PDAC). Due to high stability and tight relationship with tumor genesis and development, miRNA has been considered as a type of potential biomarkers for PDAC detection and surveillance. However, up to now, the common miRNA panel for PDAC detection is still undetermined. In order to reveal the differential miRNA expression profiles between PDAC patients(P group), chronic pancreatitis patients(C group) and healthy persons(H group), plasma samples were collected from threegroups, further the genome wide small RNA expression profiling was performed.
Project description:Currently, the majority of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) present with locally invasive and/or metastatic disease, resulting in five-year survival of less than 5%. The development of an early diagnostic test is, therefore, expected to significantly impact the patient’s prognosis. In this feasibility study, we demonstrate for the first time the utility of miRNA biomarkers for non-invasive, early detection of PDAC in urine specimens.
Project description:Transcription profiling by 3'-end sequencing of whole blood from pancreatic ductal adenocarcinoma (PDAC) patients and healthy controls for PDAC diagnosis
Project description:Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancer types, partly because it is frequently identified at an advanced stage, when surgery is no longer feasible. Therefore, early detection using minimally invasive methods such as blood tests may improve outcomes. However, studies to discover molecular signatures for the early detection of PDAC using blood tests have only been marginally successful. In the current study, a quantitative glycoproteomic approach via data-independent acquisition mass spectrometry (DIA-MS) was utilized to detect glycoproteins in 29 patient-matched PDAC tissues and sera. Total of 892 glycopeptides originated from 141 glycoproteins had PDAC associated changes beyond normal variation. We further evaluated the specificity of these serum detectable glycoproteins by comparing their abundance in 53 independent PDAC patient sera and 65 cancer-free controls. The PDAC tissue-associated glycoproteins we have identified represent an inventory of serum detectable PDAC glycoproteins as candidate biomarkers that can be potentially used for the detection of PDAC using blood tests.
Project description:Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. Late presentation of disease at the time of diagnosis is one of the major reasons for dismal prognostic outcomes for PDAC patients. Currently, there is a lack of clinical biomarkers which can be used to diagnose PDAC patients at an early resectable stage. This study performed proteomic mass spectrometry to identify novel blood-based biomarkers for early diagnosis of PDAC.
Project description:Transcription profiling by array of normal pancreas, primary pancreatic ductal adenocarcinoma (PDAC), normal liver, and pancreatic liver metastases using the Affymetrix HG-U133B array